Critical Business Considerations for Life Sciences and Medical Device Companies Amid the COVID-19 Pandemic
Life sciences and medical device companies are dealing with an unprecedented crisis. The industry is not only managing the impact of Coronavirus (COVID-19), they are also a solution provider. Companies are rapidly adapting products, services, facilities and distribution channels to aid in the pandemic response. Simultaneously, they must maintain shareholder value, navigate highly complex regulatory hurdles and compliance obligations while rethinking strategies for growth in a post-COVID-19 world.
Join a team of seasoned professionals from McDermott Will & Emery and Ernst & Young, LLP for insights and guidance on critical COVID-19-related operational, regulatory and legal developments, including:
Supply chain adaption and compliance
R&D, clinical trials and the FDA
The CARES act and accessing government funds
Restructuring and solvency strategies
See full agenda and speaker information below.
With the flood of information available to you, we want to ensure you have the opportunity to get answers to any questions that will help you assess your particular business needs.
Please note areas where you could use additional guidance in the “Questions & Comments” box so we can address the issues that are most important to you.
STAY AHEAD OF THE CURVE
Interested in receiving articles on similar topics as they are published? Subscribe for timely email updates or contact us to discuss more…
Faring through Recessions: A History of Resiliency and Lessons Learned in the Life Sciences Industry Arda Ural, Principal & Life Sciences Strategy & Operations Practice Lead
12:15 – 12:40 pm
Reconfiguring R&D and Clinical Trials: FDA Interactions and Approvals Moderator:Stephen Bernstein, Co-Chair Life Sciences Industry Practice, McDermott Will & Emery Nick Davies, Partner, EY Parthenon Vernessa Pollard, Chair, FDA Practice, McDermott Will & Emery
12:40 – 1:05 pm
Focusing on the Supply Chain: Manufacturing Inputs, Import/Export, Logistics and Compliance Moderator: Alex Jung, Managing Director, EY-Parthenon Katharine O’Connor, Partner, McDermott Will & Emery Derron Stark, Strategy & Operations – Executive Director, Ernst & Young
1:05 – 1:30 pm
Government Assistance Programs, CARES Act: Accessing Funding Supports Moderator:Kristian Werling, Co-Chair, Life Sciences Industry Practice, McDermott Will & Emery Ray Beeman, Principal and Co-leader, Washington Council Ernst & Young James Kim, Partner, McDermott Will & Emery
1:30 – 1:55 pm
Restructuring & Solvency: Creditors, Distressed Vendors & Operating through the Thicket Moderator:Felicia Perlman, Partner, McDermott Will & Emery Maris Kandestin, Partner, McDermott Will & Emery Guarav Malhotra, Principal, Ernst & Young